Surgical robotics stops being a one-company market as Medtronic and CMR challenge da Vinci
Intuitive Surgical has run the robotic surgery market essentially unopposed for two decades. Its da Vinci systems are installed in more than 8,000 hospitals worldwide and have been used in over 12 million procedures — a lead so large that "surgical robot" has functionally meant "da Vinci" for most of the industry's history. That's ending in 2026, as Medtronic's Hugo and CMR Surgical's Versius clear the FDA hurdles needed to compete directly, and both are targeting the part of the market Intuitive has never had to fight for.
Medtronic's Hugo received FDA clearance for urologic procedures in December 2025 and submitted 510(k) filings in June 2026 to expand into general surgery and gynecology — the two specialties that account for the bulk of Intuitive's procedure volume. CMR Surgical's Versius Plus cleared FDA review in December 2025 as well, and the company has already treated more than 45,000 patients globally before its U.S. debut, giving it real operating history to point to rather than just lab data.
The competitive wedge is ambulatory surgery centers, not hospitals
Neither challenger is trying to rip out an installed da Vinci and replace it — that's a fight they'd lose on switching costs and surgeon retraining alone. Instead, both are targeting ambulatory surgery centers (ASCs) and hospitals that have never had a robotics program at all. This is a meaningfully different market: ASCs handle same-day outpatient procedures, operate on thinner margins than hospitals, and have historically been priced out of robotic surgery entirely because da Vinci systems run well over a million dollars before service contracts.
CMR Surgical's Versius costs an estimated $0.75 million to $1 million; Medtronic's Hugo runs $0.9 million to $1.2 million. Both undercut da Vinci's list price, and both are explicitly designed around modular, cart-based hardware that can be wheeled between operating rooms rather than requiring a dedicated, permanently installed suite — a design choice aimed directly at space-constrained ASCs that can't dedicate an entire room to a single robot.
Why this took twenty years to happen
Intuitive's moat was never really the hardware — it was the regulatory and clinical-evidence barrier to entry. Getting a surgical robot through FDA clearance for a new procedure type requires extensive trial data, and building surgeon trust requires years of published outcomes at scale. Medtronic and CMR have spent the last several years accumulating exactly that: procedure-specific clearances rather than a single broad approval, and real-world case volume (CMR's 45,000 patients) that gives hospital purchasing committees something concrete to evaluate against da Vinci's track record.
That patience is now paying off in the form of overlapping clearances across urology, general surgery, and gynecology — the specific procedure categories that make up most of the addressable market Intuitive has owned outright.
What hospital systems and investors should watch next
The near-term signal to track isn't headline market share — Intuitive's installed base is too large to move quickly — it's ASC adoption rates and whether Medtronic or CMR can convert first-time robotics buyers into repeat customers as they add locations. A hospital system standardizing on Hugo across its outpatient network, rather than buying a single unit as a pilot, would be the clearest sign that the two-decade monopoly phase is actually over rather than just facing its first real dent.
For health systems evaluating a first robotics purchase, 2026 is the first year it makes sense to run a genuine bake-off between three FDA-cleared platforms instead of defaulting to da Vinci by lack of alternatives — and the $200,000-plus price gap between da Vinci and its new competitors is large enough that total cost of ownership, not just brand recognition, now belongs in that evaluation.